Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Comorbidity and Comedication During Prescription of ALNA® (Tamsulosin) for Patients With BPH (Benign Prostatic Hyperplasia)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02245503

Enrollment

7391

Registered

2014-09-19

Start date

2003-05-31

Completion date

Unknown

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Brief summary

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

Interventions

DRUGTamsulosin

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Indication for the treatment with ALNA according to its summary of product characteristics (SPC)

Exclusion criteria

* Patients fulfilling one of the general or specific contraindications listed in the ALNA SPC, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency cannot be included in the study

Design outcomes

Primary

Measure	Time frame
Collection of information on concomitant diseases	day 1
Collection of information on concomitant treatment	day 1

Secondary

Measure	Time frame
Number of patients with adverse drug reactions	up to 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026